Tumor-associated Macrophages Infiltration is Associated with Peritumoral Lymphangiogenesis and Poor Prognosis in Lung Adenocarcinoma

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2010 Aug 3

PMID 20676804

Citations 69

Authors

Bi Cheng Zhang

Juan Gao

Jun Wang

Zhi Guo Rao

Bao Cheng Wang

Jian Fei Gao

Affiliations

Soon will be listed here.

Abstract

Tumor-associated macrophages (TAMs) have been implicated in promoting tumor progression. Nowadays, adenocarcinoma has surpassed squamous cell carcinoma as the most frequent type of lung cancer, but in lung adenocarcinoma, the correlation of TAMs with lymphangiogenesis patients remains unclear. The aim of this study was to examine the relationship between TAMs and lymphangiogenesis and the lung adenocarcinoma patients' prognosis. Tumor specimens from 65 patients with lung adenocarcinoma were determined for TAMs count and lymphatic microvessel density (LMVD) by immunohistochemistry. A positive correlation existed between TAMs count and D2-40-positive peritumoral LMVD (r=0.069, P<0.001). TAMs infiltration was significantly associated with P-TNM staging (P=0.042) and lymph node metastasis (P=0.037), and peritumoral LMVD was correlated with lymph node metastasis (P=0.003). A significant difference in overall survival was detected not only between tumors with a high TAMs count and a low TAMs count (P=0.009) but also between tumors with a high peritumoral LMVD and a low peritumoral LMVD (P=0.005). Both TAMs count and peritumoral LMVD were independent prognostic factors for overall survival. Our results indicate that TAMs infiltration correlates with tumor lymphangiogenesis and poor survival in lung adenocarcinoma.

Citing Articles

Evaluation of Tumor-Associated Macrophages and Micro-Vessel Density in Verrucous Carcinoma and Squamous Cell Carcinoma of the Oral Cavity.

Kadeh H, Derakhshanfar G, Rezaei Mehr O Adv Biomed Res. 2024; 13:67.

PMID: 39434951 PMC: 11493219. DOI: 10.4103/abr.abr_467_23.

Functional exploration and drug prediction on programmed cell death-related biomarkers in lung adenocarcinoma.

Zhang X, Liu T, Hao Y, Guo H, Li B Heliyon. 2024; 10(17):e36616.

PMID: 39281570 PMC: 11401088. DOI: 10.1016/j.heliyon.2024.e36616.

The role of tumor-associated macrophages in tumor immune evasion.

Huang R, Kang T, Chen S J Cancer Res Clin Oncol. 2024; 150(5):238.

PMID: 38713256 PMC: 11076352. DOI: 10.1007/s00432-024-05777-4.

Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.

Zou R, Zhong X, Liang K, Zhi C, Chen D, Xu Z BMC Cancer. 2023; 23(1):403.

PMID: 37142967 PMC: 10161664. DOI: 10.1186/s12885-023-10906-2.

Interaction of tumor‑associated macrophages with stromal and immune components in solid tumors: Research progress (Review).

Kazakova A, Sudarskikh T, Kovalev O, Kzhyshkowska J, Larionova I Int J Oncol. 2023; 62(2).

PMID: 36660926 PMC: 9851132. DOI: 10.3892/ijo.2023.5480.

References

Schoppmann S, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S . VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery. 2006; 139(6):839-46. DOI: 10.1016/j.surg.2005.12.008. View

Edwards J, Zhang X, Frauwirth K, Mosser D . Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006; 80(6):1298-307. PMC: 2642590. DOI: 10.1189/jlb.0406249. View

Stacker S, Caesar C, Baldwin M, Thornton G, Williams R, Prevo R . VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001; 7(2):186-91. DOI: 10.1038/84635. View

Schoppmann S, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C . Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002; 161(3):947-56. PMC: 1867252. DOI: 10.1016/S0002-9440(10)64255-1. View

Ryder M, Ghossein R, Ricarte-Filho J, Knauf J, Fagin J . Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008; 15(4):1069-74. PMC: 2648614. DOI: 10.1677/ERC-08-0036. View

Stacker S, Farnsworth R, Karnezis T, Shayan R, Smith D, Paavonen K . Molecular pathways for lymphangiogenesis and their role in human disease. Novartis Found Symp. 2007; 281:38-43. DOI: 10.1002/9780470062128.ch4. View

Allavena P, Sica A, Solinas G, Porta C, Mantovani A . The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2007; 66(1):1-9. DOI: 10.1016/j.critrevonc.2007.07.004. View

Zhang B, Wang J, Gao J, Guo Y, Chen X, Wang B . Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem. 2009; 107(1):134-43. DOI: 10.1002/jcb.22110. View

Takanami I, Takeuchi K, Kodaira S . Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999; 57(2):138-42. DOI: 10.1159/000012021. View

10.

Martinez F, Sica A, Mantovani A, Locati M . Macrophage activation and polarization. Front Biosci. 2007; 13:453-61. DOI: 10.2741/2692. View

11.

Deniz H, Kibar Y, Guldur M, Bakir K . Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?. Pathol Res Pract. 2009; 205(11):749-52. DOI: 10.1016/j.prp.2009.06.001. View

12.

Kim H, Sung W, Lee S, Chang S, Park Y . Lymphatic vessel densities of lymph node-negative prostate adenocarcinoma in Korea. Pathol Res Pract. 2008; 205(4):249-54. DOI: 10.1016/j.prp.2008.10.005. View

13.

Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I . Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res. 2005; 11(20):7344-53. DOI: 10.1158/1078-0432.CCR-05-1077. View

14.

Kadota K, Huang C, Liu D, Ueno M, Kushida Y, Haba R . The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008; 44(7):1057-67. DOI: 10.1016/j.ejca.2008.03.012. View

15.

de Visser K, Coussens L . The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006; 13:118-137. DOI: 10.1159/000092969. View

16.

Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A . First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Rev Anticancer Ther. 2009; 9(4):425-35. DOI: 10.1586/era.09.3. View

17.

Mantovani A . La mala educación of tumor-associated macrophages: Diverse pathways and new players. Cancer Cell. 2010; 17(2):111-2. DOI: 10.1016/j.ccr.2010.01.019. View

18.

Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, Satoh M . Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005; 104(8):1668-77. DOI: 10.1002/cncr.21366. View

19.

Lee C, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery K, Zhu S . Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008; 14(5):1423-30. DOI: 10.1158/1078-0432.CCR-07-1712. View

20.

Solinas G, Germano G, Mantovani A, Allavena P . Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009; 86(5):1065-73. DOI: 10.1189/jlb.0609385. View